Stock Events

Stock Events

Inovio Pharmaceuticals 

$1.0900
348
-$0.53-32.72%Friday 08:56

Statistics

Day High
1.42
Day Low
0.9863
52W High
2.28
52W Low
0.795
Volume
2,804,789
Avg. Volume
-
Mkt Cap
112.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q3 2025
Q1 2026
Q2 2026
Next
-0.87
-0.6
-0.34
-0.07
Expected EPS
-0.196667
Actual EPS
N/A

Financials

-130,686.15%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
65,000Revenue
-84.95MNet Income

Analyst Ratings

$4.00Average Price Target
The highest estimate is ⁦5.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INO.BOATS. It's not an investment recommendation.
Tesla
63
TSLA
Apple
60
AAPL
Microsoft
56
MSFT
NIO
48
NIO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.66B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to Inovio's focus area.
Moderna
MRNA
Mkt Cap88.52B
Moderna competes in the mRNA vaccine space, directly rivalling Inovio's DNA-based vaccine technology.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech, in partnership with Pfizer, competes in the development of mRNA vaccines, a similar field to Inovio's DNA vaccine efforts.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, with its broad portfolio including mRNA vaccines developed in partnership with BioNTech, competes in the vaccine market alongside Inovio.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the development of vaccines, including for COVID-19, similar to Inovio.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in the vaccine space, including COVID-19 vaccines, which is a direct competition to Inovio's vaccine development efforts.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes in the broad pharmaceuticals and vaccines market, including partnerships for COVID-19 vaccines, overlapping with Inovio's market.
Sanofi
SNY
Mkt Cap106.24B
Sanofi competes in the global vaccines market, including efforts in developing COVID-19 vaccines, making it a competitor to Inovio.
Arcturus Therapeutics
ARCT
Mkt Cap313.51M
Arcturus Therapeutics is involved in the development of mRNA vaccines and therapeutics, competing in the same space as Inovio's DNA-based approaches.

About

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Show More
CEO
ISIN
US45773H4092

Listings

MU
DE
GBMB.MU
STU
DE
GBM.STU
STU
DE
GBMB.STU
MU
DE
GBM.MU

0 Comments

Share your thoughts

FAQs

What is Inovio Pharmaceuticals stock price today?▼
The current price of INO.BOATS is $1.09 USD — it has decreased by -32.72% in the past 24 hours. Watch Inovio Pharmaceuticals stock price performance more closely on the chart.
What is Inovio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Inovio Pharmaceuticals stocks are traded under the ticker INO.BOATS.
What is Inovio Pharmaceuticals market cap?▼
Today Inovio Pharmaceuticals has the market capitalization of 112.7M
When is the next Inovio Pharmaceuticals earnings date?▼
Inovio Pharmaceuticals is going to release the next earnings report on November 10, 2026.
What were Inovio Pharmaceuticals earnings last quarter?▼
INO.BOATS earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.22 USD resulting in a +67.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inovio Pharmaceuticals revenue for the last year?▼
Inovio Pharmaceuticals revenue for the last year amounts to 65,000 USD.
What is Inovio Pharmaceuticals net income for the last year?▼
INO.BOATS net income for the last year is -84.95M USD.
In which sector is Inovio Pharmaceuticals located?▼
Inovio Pharmaceuticals operates in the Other sector.
When did Inovio Pharmaceuticals complete a stock split?▼
The last stock split for Inovio Pharmaceuticals was on January 25, 2024 with a ratio of 1:12.